申请人:DANA-FARBER CANCER INSTITUTE, INC.
公开号:US20210347772A1
公开(公告)日:2021-11-11
Disclosed are compounds that possess inhibitory activity against LRRK2. Also disclosed are pharmaceutical compositions containing the compounds and methods of using the compounds to treat diseases and disorders including neurodegenerative diseases and disorders such as Parkinson's disease, and brain cancer (e.g., gliomas and glioblastomas).